Ardelyx Inc (ARDX) Stock Price, Quote & News

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 745 1700

Website: www.ardelyx.com

Address:

400 Fifth Avenue, Suite 210, Waltham, United States

findingthestock Jul. 15 at 6:24 AM

$ARDX Two years later stock trading in 5s and all these analysts had price targets of 15+ They should put out a disclaimer and say their price targets are meant for 10 year+ window so maybe by 2034

0 · Reply

findingthestock Jul. 15 at 6:15 AM

$ARDX lol Laura Chico and all these analysts haven’t hit their price targets in years!! Why would anyone listen to these analysts Chico has had double digit targets for years for Ardelyx. Without any buyout for this stock to get to double digits isn’t realistic https://stockanalysis.com/analysts/laura-chico/

0 · Reply

TheYoungGeologist Jul. 14 at 10:15 PM

$ARDX wtf?

1 · Reply

PompousPilot Jul. 14 at 10:13 PM

$ARDX Has Dave made a purchase?

1 · Reply

Coolandfast Jul. 14 at 8:29 PM

$ARDX $MSAI $TGE looks like a lot of profit taking now on BMGL, chasing never works after the fact! Time to load up on MARA before it takes off and lands a big AI deal.

0 · Reply

WestTexasTycoon Jul. 14 at 8:27 PM

$ARDX defintely a quiet period here.

0 · Reply

imlivinit Jul. 14 at 8:17 PM

$ARDX up….

0 · Reply

TradeX_ Jul. 14 at 8:02 PM

Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $ARDX $MSAI $TGE (R

0 · Reply

jaw02 Jul. 14 at 6:55 PM

$ARDX Slow day. Came across this just a few min ago. Assuming its just a simple, data entry error. Should be Tempest Therapeutics as the contact. They are developing amezalpat. But wait, isn't that the one in the same co that Raab was the chairman of the board? He left there May 2026. I'd love nothing more than a Freudian slip and an entry in to the cancer field. https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/ema-pe-0000232449

2 · Reply

ToadTrader Jul. 14 at 6:50 PM

$ARDX LOL Sideways, again! Thought I was gonna see some "ACTION" here today, loaded up with shares $5.08.... ste a trailing stop and went about my day! I'll call it "EVEN" as it tapped out GREEN for $1.87 (TOTAL!) on 100-shares! I will say, that general scalping both yesterday and today, has been skinny returns.... Then I always say.... Some GREEN in a day is a good thing! Stacked up 132 GREEN Days (YTD) thus feeling good in the effort! I'll be watching.... waiting as needed.... looking for the next proper entry! You all take care.... TRade your Plan... Trade Safe! CHEERS!

1 · Reply

Jefferies says Ardelyx CMS appeal loss ‘shouldn’t fundamentally change anything’

2026-06-16T11:57:58.000Z - 4 weeks ago

Ardelyx assumed with a Buy at Ladenburg

Jun 3, 2026, 9:55 AM EDT - 5 weeks ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2026

May 26, 2026, 8:00 AM EDT - 7 weeks ago

Ardelyx Proxy statement: Proxy filing

May 19, 2026, 8:01 AM EDT - 2 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026

May 19, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Proxy statement: Proxy filing

May 7, 2026, 8:01 AM EDT - 2 months ago

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

2026-04-30T21:07:15.000Z - 2 months ago

Ardelyx reports Q1 EPS (15c), consensus (14c)

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Ardelyx Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

Ardelyx Quarterly report: Q1 2026

Apr 30, 2026, 4:01 PM EDT - 2 months ago

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Proxy statement: Proxy filing

Apr 27, 2026, 8:01 AM EDT - 2 months ago

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Apr 23, 2026, 8:01 AM EDT - 2 months ago

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

2026-04-22T11:54:28.000Z - 2 months ago

Jade Biosciences appoints Edward Conner as chief medical officer

JBIO

2026-04-20T12:50:41.000Z - 3 months ago

Ardelyx appoints Ettenberg as Chief Legal Officer

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

BMY

Apr 16, 2026, 8:01 AM EDT - 3 months ago

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

2026-04-01T12:17:42.000Z - 3 months ago

Ardelyx appoints Rajani Dinavahi as chief medical officer

Apr 1, 2026, 8:01 AM EDT - 3 months ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 10, 2026, 4:20 PM EDT - 4 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:05 PM EDT - 4 months ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

2026-03-05T13:09:46.000Z - 4 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA

Mar 4, 2026, 8:00 AM EST - 4 months ago

Ardelyx to Participate in Upcoming Investor Conferences

2026-02-24T13:18:35.000Z - 5 months ago

Ardelyx, LPGA announce multi-year partnership

Feb 24, 2026, 8:00 AM EST - 5 months ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

2026-02-20T11:12:08.000Z - 5 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-19T22:00:37.000Z - 5 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 5 months ago

Ardelyx Slides: Q4 2025

Feb 19, 2026, 4:01 PM EST - 5 months ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 5, 2026, 8:00 AM EST - 5 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

2026-02-03T13:41:00.000Z - 5 months ago

Ardelyx receives new patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 5 months ago

Ardelyx Receives New Patent for Tenapanor

2026-01-29T14:35:34.000Z - 5 months ago

Ardelyx price target raised to $13 from $10 at TD Cowen

2026-01-28T13:38:18.000Z - 5 months ago

Ardelyx announces first patient dosed in ACCEL

Jan 28, 2026, 8:29 AM EST - 5 months ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

2026-01-27T11:25:47.000Z - 6 months ago

Ardelyx price target raised to $15 from $8 at Jefferies

2026-01-09T12:45:43.000Z - 6 months ago

Ardelyx price target raised to $14 from $11 at Citi

2026-01-09T11:00:13.000Z - 6 months ago

Ardelyx price target raised to $17 from $14 at BTIG

2026-01-08T21:35:56.000Z - 6 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

Jan 8, 2026, 8:30 AM EST - 6 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Nov 19, 2025, 11:30 AM EST - 8 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:30 AM EST - 8 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 7, 2025, 4:05 PM EST - 8 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 5, 2025, 8:00 AM EST - 8 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 9 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Quarterly report: Q3 2025

Oct 30, 2025, 4:30 PM EDT - 9 months ago

Ardelyx Earnings release: Q3 2025

Oct 30, 2025, 4:01 PM EDT - 9 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:01 AM EDT - 9 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 21, 2025, 8:00 AM EDT - 9 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 13, 2025, 8:35 AM EDT - 9 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:30 AM EDT - 9 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Sep 9, 2025, 11:30 AM EDT - 11 months ago

Ardelyx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 11 months ago

Ardelyx Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:35 AM EDT - 11 months ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 11 months ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q2 2025

Aug 4, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q2 2025

Aug 4, 2025, 4:08 PM EDT - 1 year ago

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

May 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 6, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings release: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Ardelyx Slides: Corporate Presentation

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 24, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:02 PM EDT - 1 year ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 1 year ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Ardelyx Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 8:02 AM EDT - 1 year ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 9:50 AM EST - 1 year ago

Ardelyx Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings Call Transcript: Q4 2024

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Annual report: Q4 2024

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings release: Q4 2024

Feb 20, 2025, 7:30 AM EST - 1 year ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

findingthestock Jul. 15 at 6:24 AM

$ARDX Two years later stock trading in 5s and all these analysts had price targets of 15+ They should put out a disclaimer and say their price targets are meant for 10 year+ window so maybe by 2034

0 · Reply

findingthestock Jul. 15 at 6:15 AM

0 · Reply

TheYoungGeologist Jul. 14 at 10:15 PM

$ARDX wtf?

1 · Reply

PompousPilot Jul. 14 at 10:13 PM

$ARDX Has Dave made a purchase?

1 · Reply

Coolandfast Jul. 14 at 8:29 PM

$ARDX $MSAI $TGE looks like a lot of profit taking now on BMGL, chasing never works after the fact! Time to load up on MARA before it takes off and lands a big AI deal.

0 · Reply

WestTexasTycoon Jul. 14 at 8:27 PM

$ARDX defintely a quiet period here.

0 · Reply

imlivinit Jul. 14 at 8:17 PM

$ARDX up….

0 · Reply

TradeX_ Jul. 14 at 8:02 PM

0 · Reply

jaw02 Jul. 14 at 6:55 PM

2 · Reply

ToadTrader Jul. 14 at 6:50 PM

1 · Reply

Cameohitch Jul. 14 at 6:42 PM

$ARDX "In a report released today, Wedbush maintained a Buy rating on Ardelyx, with a price target of $19.00." From Laura Chico. https://www.tipranks.com/news/blurbs/ardelyx-ardx-receives-a-buy-from-wedbush-blurbs-news https://www.tipranks.com/stocks/ardx/forecast

0 · Reply

IMADORK Jul. 14 at 5:25 PM

$ARDX Here’s a thesis: Ironwood (a very small cap biotech) needed a partnership like the one they have with the BIG pharma ABBV, to scale up and get Linzess to way more people than they otherwise could and generate mucho more revenue. Is this potentially the same rationale/dynamic with ArdX? I mean ArdX looking for a partnership with a BIG pharma to get their BIG Pharma “Muscle” and accesses to get IBS and X to way more people and generate greater revenues? Below is a copy from Grok.

2 · Reply

crypto_biotech Jul. 14 at 4:56 PM

$ARDX Mike has a good post. Take the time to read and understand the AI response. The overall analysis is encompassing: https://grok.com/share/bGVnYWN5_8b474b0b-3243-4ce1-8d6d-b4fbbfd945bf

1 · Reply

tbone55 Jul. 14 at 2:21 PM

$ARDX my monthly salary reached me and all going into ardelyx. 20% position by now. average price paid is around 5. no way this is not at 15 in a few years. hard for it go lower than 4 imo so very good risk reward.

0 · Reply